A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 32 days later Jul 2030 → Sep 2030
See other at-risk trials from Eli Lilly

Record History

  1. Primary and study completion pushed from Jul 2030 to Sep 2030
    • Trial sites expanded: 9 → 12 locations
    • Start date pushed from Oct 2026 to Nov 2026
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Dementia
1,982 trials monitored
See 105 trials at risk
Alzheimer's Disease
1,255 trials monitored
See 68 trials at risk
The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD). For each participant, the study will last up to approximately 84 weeks and will include visits every 4 weeks.
Trial Details
NCT Number NCT07838155
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Alzheimer Disease
Related terms Alzheimer Disease
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov